Jakub Swiercz

VP R&D @ Alesta Therapeutics

About

Seasoned project leader with more than ten years of relevant experience leading interdisciplinary projects in biotech and academia. Expertise in the drug discovery in the fields of Oncology and Immuno-Oncology. Proven interpersonal skills and experience in leading cross-functional teams.

Country

Belgium

City

Charleroi Metropolitan Area

Industry

Biotechnology

Skill

Molecular Biology, Pharmacology, target discovery, Cell Biology, Cell, Biochemistry, Cell Culture, In Vitro, PCR, Protein Expression, Life Sciences, Animal Models, Western Blotting, Assay Development, Biotechnology, Science, Purification, Drug Discovery, Project Coordination, Research and Development (R&D)

Experience

VP R&D

Alesta Therapeutics

2021-6 - Present · 5 yrs 4 mos

Leiden, South Holland, Netherlands

Leveraging cancer metabolism for patient benefits.

Managing Director

JakOnco

2021-5 - Present · 5 yrs 5 mos

Nivelles, Walloon Region, Belgium

Head of Cancer Biology

EPICS Therapeutics

2019-9 - 2021-5 · 1 yr 9 mos

Gosselies

Head of In Vitro Pharmacology & Screening

iTeos Therapeutics

2015-7 - 2019-8 · 4 yrs 2 mos

Gosselies

• Leader of the In Vitro Pharmacology. Directing research aimed at target identification, validation and characterizing mechanisms of action of new therapeutics • Project Leader and developer of iTeos target discovery platform dedicated to the identification of novel immuno-oncology targets • Project Leader in immuno-oncology and oncology; from target validation to early clinical development in a matrix organization. Definition, validation, implementation, and management of projects objectives, milestones, budgets, staff, and resources. Responsible for program visibility and presentation on scientific and business level • Coordination and oversight of collaborations with academic and industrial partners

Project Leader

Max Planck Institute for Heart and Lung Research

2009-9 - 2015-6 · 5 yrs 10 mos

Bad Nauheim, Germany

• Led the team responsible for identification and development of anti-Plexin-B1 monoclonal antibodies with therapeutic potential o Managed in house work and collaboration with biotech partners interested in antibody commercialization • Managed collaboration with biotech company on co-development of small molecule inhibitor of Plexin-Semaphorin signalling

Postdoctoral Fellow

University of Heidelberg

2004-9 - 2009-8 · 5 yrs

Heidelberg

• Responsible for the equipping and running of the high-throughput (HT) screening laboratory of Pharmacology Institute • Led a team of 3 scientists performing siRNA-based HT-screens using a kinase library

Education

Heidelberg University

Molecular Pharmacology

1999 - 2004 · 5 yrs

Doctoral Thesis with the title: “The interaction of plexin-B family members with Rho Guanine Nucleotide Exchange Factor proteins: mechanisms and functions of Sema4D induced RhoA activation“, defended in August 2004 (summa cum laude) Thesis awarded with ”Joachim Siebeneicher Promotionspreis“ for Biomedical Research, 2005